Trial reportJournal of clinical pathology2005
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
Trial report in Journal of clinical pathology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- FKBPL: a marker of good prognosis in breast cancer.Oncotarget · 2015Pooled it
- Trial
- Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.Breast cancer research : BCR · 2020Trial
- Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Trial
- PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients.NPJ breast cancer · 2022Article
- Digital Image Analysis of Ki-67 Stained Tissue Microarrays and Recurrence in Tamoxifen-Treated Breast Cancer Patients.Clinical epidemiology · 2020Article
- Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen.Journal of breast cancer · 2018Article
- Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.BMC cancer · 2018Article
- Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.Breast cancer research and treatment · 2017Article
- Androgen Receptor Expression in an Indian Breast Cancer Cohort with Relation to Molecular Subtypes and Response to Neoadjuvant Chemotherapy - a Prospective Clinical Study.Breast care (Basel, Switzerland) · 2017Article
- ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.BMC cancer · 2016Article
- The prognostic significance of Wnt-5a expression in primary breast cancer is extended to premenopausal women.PloS one · 2013Article
- Article
- Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.Molecular oncology · 2012Article
- Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?Nature reviews. Clinical oncology · 2012Review
- The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients.BMC cancer · 2012Article
- Stromal expression of β-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer.The Journal of molecular diagnostics : JMD · 2011Article
- Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features.The American journal of pathology · 2010Article
- RSK in tumorigenesis: connections to steroid signaling.Steroids · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubgroups of breast cancer that have an impaired response to endocrine treatment, despite hormone receptor positivity, are still poorly defined. Breast cancer can be subdivided according to standard pathological parameters including histological type, grade, and assessment of proliferation. These parameters are the net result of combinations of genetic alterations effecting tumour behaviour and could potentially reflect subtypes that respond differently to endocrine treatment.
aimsTo investigate the usefulness of these parameters as predictors of the response to tamoxifen in premenopausal women with breast cancer. MATERIALS/
methodsClinically established pathological parameters were assessed and related to the tamoxifen response in 500 available tumour specimens from 564 premenopausal patients with breast cancer randomised to either two years of tamoxifen or no treatment with 14 years of follow up. Proliferation was further evaluated by immunohistochemical Ki-67 expression.
resultsOestrogen receptor positive ductal carcinomas responded as expected to tamoxifen, whereas the difference in recurrence free survival between control and tamoxifen treated patients was less apparent in the relatively few lobular carcinomas. For histological grade, there was no obvious difference in treatment response between the groups. The relation between proliferation and tamoxifen response seemed to be more complex, with a clear response in tumours with high and low proliferation, whereas tumours with intermediate proliferation defined by Ki-67 responded more poorly.
conclusionsClinically established pathology parameters seem to mirror the endocrine treatment response and could potentially be valuable in future treatment decisions for patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.